Dermata Therapeutics (DRMA) investor relations material

Company overview and business model

• Focuses on developing and commercializing science-backed skincare products for common and underserved skin conditions, shifting from prescription (Rx) to direct-to-consumer (DTC) and B2B channels as of September 2025.

• Leverages clinical dermatology expertise and proprietary Spongilla lacustris-based technology for unique topical treatments, aiming to simplify consumer skincare routines.

• Plans to launch its first cosmetic product, the Foundational Treatment, in mid-2026, with future products targeting specific consumer needs, including sensitive skin.

• Exploring non-invasive topical delivery of botulinum toxin for aesthetic and medical skin conditions, expanding potential applications for dermatologists and aestheticians.

Financial performance and metrics

• Has not generated revenue or commercialized any products to date; operations funded primarily through equity and debt sales totaling approximately $84.1 million since inception.

• Reported net losses of $1.8 million for Q1 2026 and $7.6 million for FY 2025, with an accumulated deficit of $75.1 million as of March 31, 2026.

• Public float valued at $3,955,179.64 based on 3,189,661 shares held by non-affiliates at $1.24 per share as of May 21, 2026.

• Raised $2.0 million in January 2026 via an at-the-market offering, paying $67,000 in fees; no remaining capacity under this agreement.

Use of proceeds and capital allocation

• Net proceeds from securities sales and any exercise of convertible securities will be used for working capital and general corporate purposes.

• Pending use, proceeds will be invested in short-term, interest-bearing instruments or investment-grade securities.